Literature DB >> 28554490

Candidate gene analysis for Alzheimer's disease in adults with Down syndrome.

Joseph H Lee1, Annie J Lee2, Lam-Ha Dang3, Deborah Pang4, Sergey Kisselev5, Sharon J Krinsky-McHale4, Warren B Zigman4, José A Luchsinger6, Wayne Silverman7, Benjamin Tycko5, Lorraine N Clark8, Nicole Schupf9.   

Abstract

Individuals with Down syndrome (DS) overexpress many genes on chromosome 21 due to trisomy and have high risk of dementia due to the Alzheimer's disease (AD) neuropathology. However, there is a wide range of phenotypic differences (e.g., age at onset of AD, amyloid β levels) among adults with DS, suggesting the importance of factors that modify risk within this particularly vulnerable population, including genotypic variability. Previous genetic studies in the general population have identified multiple genes that are associated with AD. This study examined the contribution of polymorphisms in these genes to the risk of AD in adults with DS ranging from 30 to 78 years of age at study entry (N = 320). We used multiple logistic regressions to estimate the likelihood of AD using single-nucleotide polymorphisms (SNPs) in candidate genes, adjusting for age, sex, race/ethnicity, level of intellectual disability and APOE genotype. This study identified multiple SNPs in APP and CST3 that were associated with AD at a gene-wise level empirical p-value of 0.05, with odds ratios in the range of 1.5-2. SNPs in MARK4 were marginally associated with AD. CST3 and MARK4 may contribute to our understanding of potential mechanisms where CST3 may contribute to the amyloid pathway by inhibiting plaque formation, and MARK4 may contribute to the regulation of the transition between stable and dynamic microtubules.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APP; Alzheimer disease; CST3; Candidate genes; Dementia; Down syndrome; Gene mapping; MARK4

Mesh:

Substances:

Year:  2017        PMID: 28554490      PMCID: PMC5603247          DOI: 10.1016/j.neurobiolaging.2017.04.018

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  62 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

2.  A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD.

Authors:  R C Dodel; Y Du; C Depboylu; A Kurz; B Eastwood; M Farlow; W H Oertel; U Müller; M Riemenschneider
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

3.  Increased plasma amyloid beta protein 1-42 levels in Down syndrome.

Authors:  P D Mehta; A J Dalton; S P Mehta; K S Kim; E A Sersen; H M Wisniewski
Journal:  Neurosci Lett       Date:  1998-01-23       Impact factor: 3.046

4.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

5.  Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome.

Authors:  Warren B Zigman; Nicole Schupf; Edmund C Jenkins; Tiina K Urv; Benjamin Tycko; Wayne Silverman
Journal:  Neurosci Lett       Date:  2007-02-11       Impact factor: 3.046

6.  Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome.

Authors:  T Tokuda; T Fukushima; S Ikeda; Y Sekijima; S Shoji; N Yanagisawa; A Tamaoka
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

7.  Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.

Authors:  B Rumble; R Retallack; C Hilbich; G Simms; G Multhaup; R Martins; A Hockey; P Montgomery; K Beyreuther; C L Masters
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

8.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

9.  Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome.

Authors:  Kin Y Mok; Emma L Jones; Marisa Hanney; Denise Harold; Rebecca Sims; Julie Williams; Clive Ballard; John Hardy
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

10.  MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.

Authors:  Harald Lund; Elin Gustafsson; Anne Svensson; Maria Nilsson; Margareta Berg; Dan Sunnemark; Gabriel von Euler
Journal:  Acta Neuropathol Commun       Date:  2014-02-17       Impact factor: 7.801

View more
  9 in total

Review 1.  Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse models.

Authors:  Y Eugene Yu; Zhuo Xing; Catherine Do; Annie Pao; Eun Joon Lee; Sharon Krinsky-McHale; Wayne Silverman; Nicole Schupf; Benjamin Tycko
Journal:  Prog Brain Res       Date:  2019-10-24       Impact factor: 2.453

Review 2.  Exosomal biomarkers in Down syndrome and Alzheimer's disease.

Authors:  Eric D Hamlett; Aurélie Ledreux; Huntington Potter; Heidi J Chial; David Patterson; Joaquin M Espinosa; Brianne M Bettcher; Ann-Charlotte Granholm
Journal:  Free Radic Biol Med       Date:  2017-09-05       Impact factor: 7.376

Review 3.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

4.  Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome.

Authors:  Melissa Petersen; Fan Zhang; Sharon J Krinsky-McHale; Wayne Silverman; Joseph H Lee; Deborah Pang; James Hall; Nicole Schupf; Sid E O'Bryant
Journal:  Alzheimers Dement (Amst)       Date:  2020-04-17

5.  Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome.

Authors:  Sid E O'Bryant; Fan Zhang; Wayne Silverman; Joseph H Lee; Sharon J Krinsky-McHale; Deborah Pang; James Hall; Nicole Schupf
Journal:  Alzheimers Dement (Amst)       Date:  2020-05-21

6.  Alzheimer's risk and quality of life: History of Down syndrome as a case in point.

Authors:  Wayne Silverman; Sharon Krinsky-McHale
Journal:  Alzheimers Dement (Amst)       Date:  2021-03-31

7.  Genetic dissection of down syndrome-associated alterations in APP/amyloid-β biology using mouse models.

Authors:  Justin L Tosh; Elena R Rhymes; Paige Mumford; Heather T Whittaker; Laura J Pulford; Sue J Noy; Karen Cleverley; Matthew C Walker; Victor L J Tybulewicz; Rob C Wykes; Elizabeth M C Fisher; Frances K Wiseman
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

8.  Endosomal structure and APP biology are not altered in a preclinical mouse cellular model of Down syndrome.

Authors:  Claudia Cannavo; Karen Cleverley; Cheryl Maduro; Paige Mumford; Dale Moulding; Elizabeth M C Fisher; Frances K Wiseman
Journal:  PLoS One       Date:  2022-05-11       Impact factor: 3.240

Review 9.  The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology.

Authors:  Benjamin L Handen; Ira T Lott; Bradley T Christian; Nicole Schupf; Sid OBryant; Mark Mapstone; Anne M Fagan; Joseph H Lee; Dana Tudorascu; Mei-Cheng Wang; Elizabeth Head; William Klunk; Beau Ances; Florence Lai; Shahid Zaman; Sharon Krinsky-McHale; Adam M Brickman; H Diana Rosas; Annie Cohen; Howard Andrews; Sigan Hartley; Wayne Silverman
Journal:  Alzheimers Dement (Amst)       Date:  2020-08-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.